Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | PLAUR | Q03405 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372295 | 0.90 | ALB (0.38) | ALBSLC6A9FOLH1CACNA2D1CACNA1B | |
| SCHEMBL4369094 | 0.87 | ALB (0.39) | ALBSLC6A9FOLH1CACNA2D1CACNA1B | |
| SCHEMBL4359589 | 0.84 | SLC6A9 (0.39) | ALBSLC6A9LMNATACR1 | |
| SCHEMBL1673149 | 0.83 | SLC6A9 (0.39) | ALBSLC6A9FOLH1CACNA2D1CACNA1B | |
| SCHEMBL4368905 | 0.83 | ALB (0.40) | ALBSLC6A9ACELMNA | |
| SCHEMBL18709168 | 0.82 | SLC6A9 (0.37) | ALBSLC6A9FOLH1EGLN1CACNA2D1 | |
| SCHEMBL1673011 | 0.81 | SLC6A9 (0.40) | ALBSLC6A9PLAUPLAURFOLH1 | |
| SCHEMBL410472 | 0.81 | SLC6A9 (0.40) | ALBSLC6A9PLAUPLAURFOLH1 | |
| SCHEMBL2240651 | 0.80 | SLC6A9 (0.39) | ALBSLC6A9PLAUPLAURFOLH1 | |
| SCHEMBL9205301 | 0.80 | EGLN1 (0.40) | SLC6A9EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268810-B2 | Lipophilic chelates and their use in imaging | GUERBET (FR) | 2012-09-18 | — | — | US | disclosed |
| US-8268810-B2 | Lipophilic chelates and their use in imaging | GUERBET (FR) | 2012-09-18 | — | — | US | disclosed |
| US-8268810-B2 | Lipophilic chelates and their use in imaging | GUERBET (FR) | 2012-09-18 | — | — | US | disclosed |
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | GUERBET (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | GUERBET (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | GUERBET (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-1885721-B1 | METAL CHELATES OF POLYAMINOCARBOXYLIC MACROCYCLIC DERIVATIVES AND USE THEREOF IN DIAGNOSTIC IMAGING | GUERBET SA (FR) | 2009-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | SLC40A1, TSPO, SLC47A2 | ALB 1926/4885SLC6A9 229/4885PLAU 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.